Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples.


Journal

Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 15 04 2022
accepted: 01 08 2022
pubmed: 11 11 2022
medline: 23 11 2022
entrez: 10 11 2022
Statut: ppublish

Résumé

Candida auris is a nosocomial fungal pathogen of prime importance due to its global emergence and rapid spread in healthcare facilities worldwide. One important concern is that routine, conventional methods fail to identify C. auris. While molecular and protein-based assays accurately detect/identify C. auris, these methods are time-consuming, expensive, and require expertise. Therefore, the objective of the present study was to assess the potential use of a novel chromogenic medium, CHROMagar™ Candida Plus, as an economical alternative to expensive and laborious diagnostic tests. We compared CHROMagar™ Candida Plus with the standard enrichment (salt Sabouraud Dulcitol broth) medium to test the recovery efficiency of C. auris from surveillance samples. We also tested CHROMagar™ Candida Plus for its ability to distinguish C. auris from other yeast species. One hundred surveillance samples were cultured on CHROMagar™ Candida Plus and Dulcitol broth and incubated at 37 °C and 40 °C, respectively. Additionally, 32 Candida and yeast species were cultured on CHROMagar™ Candida Plus at 37 °C for three days to rule out any close resemblance to C. auris. Of 100 surveillance samples tested, 69 yielded presumptive positive C. auris exhibiting creamy pink colonies with a blue halo on CHROMagar™ Candida Plus within three days of incubation, and MALDI-TOF MS confirmed all by day 4. On the other hand, 69 of 100 surveillance samples yielded turbidity in Dulcitol broth by days 3-14 with final MALDI identification by days 5 to 17. Both media failed to identify one sample each, resulting in assay sensitivity and specificity of 99% and 97%, respectively. Of Candida and yeast species tested, 75-80% of C. metapsilosis and C. orthospilosis were misidentified as C. auris. However, previous studies indicated that these species are rarely detected in surveillance screening of C. auris. Naganishia diffluens also resembled C. auris, although it required different temperature growth (30 °C). In conclusion, CHROMagar™ Candida Plus provides rapid presumptive identification of C. auris. It would be another valuable tool in surveillance efforts to control the spread of C. auris in healthcare.

Identifiants

pubmed: 36355325
doi: 10.1007/s11046-022-00656-3
pii: 10.1007/s11046-022-00656-3
pmc: PMC9647746
doi:

Substances chimiques

Galactitol 113ZQ1Y7DD

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-534

Subventions

Organisme : CDC HHS
ID : NU50CK000516
Pays : United States
Organisme : CDC HHS
ID : NU50CK000516
Pays : United States

Informations de copyright

© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Clin Microbiol Infect. 2021 Jan 8;:
pubmed: 33429028
Mycopathologia. 2022 Feb;187(1):121-127
pubmed: 34855102
Swiss Med Wkly. 2020 Sep 25;150:w20297
pubmed: 32975306
Med Mycol. 2021 Mar 4;59(3):253-258
pubmed: 32525988
Antimicrob Resist Infect Control. 2016 Oct 19;5:35
pubmed: 27777756
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29187562
Open Forum Infect Dis. 2021 Sep 07;8(12):ofab452
pubmed: 34904116
PLoS Pathog. 2017 May 18;13(5):e1006290
pubmed: 28542486
Libyan J Med. 2010 Feb 09;5:
pubmed: 21483597
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33536293
BMC Infect Dis. 2021 May 6;21(1):425
pubmed: 33957894
J Clin Microbiol. 2015 Jun;53(6):1823-30
pubmed: 25809970
J Clin Microbiol. 2017 Oct;55(10):2996-3005
pubmed: 28747370
J Clin Microbiol. 2020 Mar 25;58(4):
pubmed: 31852764
World Med Health Policy. 2021 Dec;13(4):766-772
pubmed: 34909239
Med Mycol. 2011 Jan;49(1):98-102
pubmed: 20560864
Clin Infect Dis. 2017 Jan 15;64(2):134-140
pubmed: 27988485
Emerg Infect Dis. 2020 May;26(5):876-880
pubmed: 32310077
PLoS Pathog. 2020 Oct 22;16(10):e1008921
pubmed: 33091071
J Infect. 2019 Dec;79(6):601-611
pubmed: 31557493
Microbiol Immunol. 2009 Jan;53(1):41-4
pubmed: 19161556
Emerg Infect Dis. 2019 Sep;25(9):1780-1781
pubmed: 31310230
Diagn Microbiol Infect Dis. 2020 Dec;98(4):115168
pubmed: 32927410
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
Clin Microbiol Rev. 2017 Apr;30(2):449-479
pubmed: 28122803
Front Microbiol. 2021 Oct 07;12:757835
pubmed: 34691009

Auteurs

Anuradha Marathe (A)

Mycology Laboratory, New York State Department of Health, Wadsworth Center, Albany, NY, USA.

YanChun Zhu (Y)

Mycology Laboratory, New York State Department of Health, Wadsworth Center, Albany, NY, USA.

Vishnu Chaturvedi (V)

Mycology Laboratory, New York State Department of Health, Wadsworth Center, Albany, NY, USA.
Westchester Medical Center/New York Medical College, Valhalla, NY, USA.

Sudha Chaturvedi (S)

Mycology Laboratory, New York State Department of Health, Wadsworth Center, Albany, NY, USA. sudha.chaturvedi@health.ny.gov.
Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY, USA. sudha.chaturvedi@health.ny.gov.

Articles similaires

Vibrio Whole Genome Sequencing Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Genome, Bacterial Water Microbiology
Antifungal Agents Microbial Sensitivity Tests Drug Resistance, Fungal Candida auris Candidiasis
Biofilms Animals Mice Cell Adhesion Candidiasis
Humans Female Community-Acquired Infections Aged, 80 and over Micrococcus

Classifications MeSH